The DOI matches its Crossref record; 14 of the 16 references it cites were found in a registry or an index.
Decreased SARS-CoV-2 viral load following vaccination
Open accessPreprint — published as 10.1038/s41591-021-01316-7 · Paper page
Abstract
Beyond their substantial protection of individual vaccinees, it is hoped that the COVID-19 vaccines would reduce viral load in breakthrough infections thereby further suppress onward transmission. Here, analyzing positive SARS-CoV-2 test results following inoculation with the BNT162b2 mRNA vaccine, we find that the viral load is reduced 4-fold for infections occurring 12-28 days after the first dose of vaccine. These reduced viral loads hint to lower infectiousness, further contributing to vaccine impact on virus spread.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Some early post-implementation analyses have suggested that the mRNA vaccines also reduce the incidence of asymptomatic infection and the nasopharyngeal viral load in individuals who become infected despite the vaccination93,107, but it is yet unclear how this translates to risk of transmission.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [107]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Temporal dynamics in viral shedding and transmissibility of COVID-19
He, X., Lau, E. H. Y., Wu, P., Deng, X., Wang, J., Hao, X., Lau, Y. C., Wong, J. Y., Guan, Y., Tan, X., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0869-5 · Cited by 4,300
A guide to vaccinology: from basic principles to new developments
Pollard, A. J., & Bijker, E. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00479-7 · Cited by 1,593
Rethinking Covid-19 Test Sensitivity — A Strategy for Containment
Mina, M. J., Parker, R., & Larremore, D. B. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2025631 · Cited by 715
SARS-CoV-2 viral load predicts COVID-19 mortality
Pujadas, E., Chaudhry, F. F., McBride, R. B., Richter, F., Zhao, S., Wajnberg, A., Nadkarni, G. N., Glicksberg, B. S., Houldsworth, J., & Cordon‐Cardo, C. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30354-4 · Cited by 534
Evaluation of COVID-19 RT-qPCR Test in Multi sample Pools
Yelin, I., Aharony, N., Tamar, E. S., Argoetti, A., Messer, E., Berenbaum, D., Shafran, E., Kuzli, A., Gandali, N., Shkedi, O., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa531 · Cited by 450
Self-citationUnderstanding COVID-19 vaccine efficacy
Lipsitch, M., & Dean, N. E. (2020) · Science · doi:10.1126/science.abe5938 · Cited by 230
Chodick, G., Tene, L., Patalon, T., Gazit, S., Ben‐Tov, A., Cohen, D., & Muhsen, K. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.15985 · Cited by 189
Self-citationÇevik, M., Marcus, J. L., Buckee, C. O., & Smith, T. C. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1442 · Cited by 141
SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn
Connors, M., Graham, B. S., Lane, H. C., & Fauci, A. S. (2021) · Annals of Internal Medicine · doi:10.7326/m21-0111 · Cited by 71
Research works printed but not linked: 2
- Chodcik, G. et al. The effectiveness of the first dose of BNT162 b 2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidence. medRxiv 2021.01.27.21250612 (2021). · DOI
- Levine-Tiefenbrun, M. et al. Association of COVID-19 RT-qPCR test false-negative rate with patient age, sex and time since diagnosis. medRxiv (2020). · DOI
Cited by
Sorted by citations
Drug delivery systems for RNA therapeutics
Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349
Tregoning, J. S., Flight, K. E., Higham, S. L., Wang, Z., & Pierce, B. F. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00592-1 · Cited by 1,146
Fiolet, T., Kherabi, Y., MacDonald, C.-J., Ghosn, J., & Peiffer-Smadja, N. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.10.005 · Cited by 911
Singanayagam, A., Hakki, S., Dunning, J. W., Madon, K. J., Crone, M. A., Koycheva, A., Derqui, N., Barnett, J. L., Whitfield, M. G., Varro, R., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00648-4 · Cited by 733
Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus
Raman, B., Bluemke, D. A., Lüscher, T. F., & Neubauer, S. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac031 · Cited by 717
Metadata
- Authors
- Levine-Tiefenbrun, M., Yelin, I., Katz, R., Herzel, E., Golan, Z., Schreiber, L., Wolf, T., Nadler, V., Ben-Tov, A., Kuint, J., Gazit, S., Patalon, T., Chodick, G., & Kishony, R.
- Affiliations
- Technion – Israel Institute of Technology (IL)
- Maccabi Healthcare Services (IL)
- Tel Aviv University (IL)
- Corresponding author
- Yelin, Idan
- Kishony, Roy
- ORCID
- Venue
- Nature Medicine
- Publisher
- openRxiv
- Published
- 2021-02-08
- Volume
- 27
- Issue
- 5
- Pages
- 790-792
- ISSN
- 1078-8956 (ISSN-L)
- OpenAlex
- W3150351745
- Cited by
- 514
- References
- 16
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 19 · 2023: 67 · 2022: 166 · 2021: 242
- FWCI
- 39.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature Medicine (publishedVersion)
- medRxiv (acceptedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Israel Science Foundation (3633/19)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, COVID-19 pandemic, BNT162b2, mRNA vaccines, breakthrough infection, viral load, infectiousness, transmission reduction, vaccine effectiveness, real-world data
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Vaccination, Viral Load, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
